by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersNova Vascular LLC dba NOVARX

All Warning Letters

Nova Vascular LLC dba NOVARX

Warning LetterOpen

99 Wall Street, #878 New York , NY 10005 United StatesIssued Jun 8, 2026Center for Drug Evaluation and Research (CDER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateJun 8, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Nova Vascular LLC dba NOVARX
Location: 99 Wall Street, #878 New York , NY 10005 United States
FEI Number: N/A
Country: United States
Issue Date: June 08, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Subject

False & Misleading Claims/Misbranded (Telehealth)

Nova Vascular LLC dba NOVARX FDA Warning Letter, June 8, 2026